All In Biotech

Company

Human Genome Sciences Inc.

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

2

2 still marketed

Novel approvals

2

Approvals since 2021

1

Originals and new uses

Phase 3 trials

11

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Benlysta new use Priority reviewJul 26, 2022
  • Benlysta new use Breakthrough therapyPriority reviewDec 16, 2020
  • Benlysta new use Sep 24, 2020
  • Benlysta new use Jan 17, 2020
  • Benlysta new use Priority reviewApr 26, 2019
  • Raxibacumab new use Priority reviewOrphanJan 11, 2018
  • Raxibacumab approved NovelPriority reviewOrphanDec 14, 2012
  • Benlysta approved NovelPriority reviewMar 9, 2011

Drugs in development (0)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

No investigational drugs in Phase 2 or 3 trials under this sponsor name.

Recruiting Phase 3 trials

Largest first.

No recruiting Phase 3 trials under this sponsor name.

Marketed drugs (2)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.